BIOCON, Author at Biocon

Leaving the Biocon site!

You are now leaving the Biocon website for a Biocon affiliate site or third party site that is solely responsible for its content, including its compliance with guidelines applicable in certain geographies. Links to Biocon affiliate sites and third party sites are provided as a resource to our visitors and may not be governed by the same regulatory requirements applicable to this site and unaffiliated third party sites are subject to their own terms and data protection notices and practices. Moreover, if their third party site is subject to other country laws, regulatory requirements, data protection requirements or medical practices may differ between countries and the information provided therein may not be suitable for use in your country.

Biocon Biologics Signs Settlement and License Agreement to Commercialize Biosimilar Aflibercept Worldwide

S&P Global Places Biocon Biologics on Positive CreditWatch On Account of Accelerated Debt Reduction

Kiran Mazumdar-Shaw Honored with ‘USC Business Management Award’ at The Inaugural USC India Awards held in Mumbai

Biocon Limited to Integrate Biocon Biologics Limited to Create a Unified Global Biopharmaceutical Leader

Biocon Pharma Limited Secures U.S. FDA Tentative Approval for Carbidopa and Levodopa Extended-Release Capsules

Biocon Biologics Secures Market Entry Date for Denosumab Biosimilars in Europe and Rest of the World

Biocon Biologics’ Drug Substance Facility in Bengaluru Classified as Voluntary Action Indicated (VAI)

Biocon Pharma Limited Receives U.S. FDA Approval for Tofacitinib Extended-Release Tablets

Kiran Mazumdar-Shaw Ranked Among India’s Most Generous Women Philanthropists by EdelGive Hurun India Philanthropy List 2025

Biocon Q2FY26 Operating Revenue at Rs 4,296 Cr, Up 20% EBITDA at Rs 928 crore; Up 29%;